ATM Inhibition Drives Metabolic Adaptation via Macropinocytosis

Study Background and Research Question

Ataxia-telangiectasia mutated (ATM) kinase is a central regulator of the DNA damage response, best known for orchestrating DNA double-strand break repair, maintaining genomic stability, and modulating checkpoint control. In addition to its canonical roles, emerging research implicates ATM in cellular metabolism and nutrient sensing. Macropinocytosis, a nonselective endocytic process, enables cancer cells to scavenge extracellular nutrients under metabolic stress. While prior studies have linked macropinocytosis to oncogenic signaling (such as mutant RAS or PTEN loss), the contribution of DNA damage response inhibitors—specifically ATM kinase inhibitors—to this adaptive mechanism remained unclear. The reference study (Huang et al., 2023) addresses whether ATM inhibition can induce macropinocytosis and whether this adaptation supports cancer cell survival in nutrient-deprived microenvironments.

Key Innovation from the Reference Study

The central innovation of this work is the identification of a previously unrecognized metabolic adaptation: suppression of ATM kinase activity leads to increased macropinocytosis, enhancing nutrient uptake and promoting cancer cell survival under nutrient-poor conditions. The study further demonstrates that combining ATM inhibition with blockade of macropinocytosis synergistically suppresses tumor cell proliferation and viability, both in vitro and in vivo. These findings expose a metabolic vulnerability in ATM-inhibited cells and suggest a rationale for combinatorial therapies targeting both DNA damage response and nutrient scavenging pathways.

Methods and Experimental Design Insights

The research team employed a combination of pharmacological and genetic approaches to inhibit ATM kinase, utilizing selective ATM kinase inhibitors and gene knockdown strategies across multiple cancer models. Key experimental methods included:

• Quantification of macropinocytosis using uptake assays with fluorescently labeled dextran.
• Assessment of cell viability and proliferation under nutrient-restricted and complete media conditions.
• Metabolomic profiling of cell culture media and tumor microenvironment fluids (ascites and interstitial fluid) to quantify branched-chain amino acid (BCAA) levels.
• Combination treatments with macropinocytosis inhibitors and ATM inhibitors to dissect functional interactions.
• In vivo tumor models to validate the effect of ATM inhibition and macropinocytosis blockade on tumor growth and survival.

This multi-pronged design allowed for robust evaluation of both the cellular and systemic metabolic consequences of ATM kinase inhibition.

Core Findings and Why They Matter

Key results from the study include:

• ATM inhibition upregulates macropinocytosis: Cancer cells with suppressed ATM activity exhibited increased dextran uptake, indicating enhanced macropinocytosis, particularly under nutrient-poor conditions.
• Macropinocytosis supports survival: Inhibition of macropinocytosis in ATM-deficient cells led to marked decreases in cell proliferation and increased cell death, both in vitro and in mouse tumor models.
• BCAA supplementation modulates adaptation: Exogenous BCAAs, especially leucine and isoleucine, counteracted the increase in macropinocytosis in ATM-inhibited cells, suggesting that amino acid uptake is a key driver of this adaptive response.
• Tumor microenvironment reflects metabolic shift: Metabolomic analysis revealed decreased BCAA concentrations in the ascites and interstitial fluid of ATM-inhibited tumors, consistent with increased nutrient scavenging.

Collectively, these findings reveal a novel mechanism by which ATM functions as a tumor suppressor: by limiting the capacity of cancer cells to adapt metabolically through macropinocytosis. This has important implications for cancer therapy research, particularly in the design of combination strategies targeting both DNA damage response inhibitors and metabolic pathways.

Comparison with Existing Internal Articles

Several recent internal reviews and articles have highlighted the expanding role of ATM kinase inhibition in cancer research. For example, one analysis emphasizes the strategic integration of ATM inhibitors like AZD0156 with DNA-damaging agents and checkpoint control modulation. Another article (Unlocking ATM Inhibition for Precision Metabolic Vulnerability) discusses the potential of ATM kinase inhibitors to expose unique metabolic weaknesses in cancer cells.

What sets the reference study apart is the mechanistic connection established between ATM suppression and the induction of macropinocytosis as an adaptive, pro-survival response. While internal resources often focus on the DNA damage response and synergy with cytotoxic agents, Huang et al. provide direct evidence that ATM inhibition itself drives a metabolic adaptation that can be therapeutically exploited. This complements perspectives in other internal reviews exploring how ATM kinase inhibitors like AZD0156 can help dissect metabolic vulnerabilities in tumor models.

Limitations and Transferability

Despite robust experimental validation, the study has several limitations. Most notably, the metabolic adaptation described was demonstrated largely in preclinical models and under defined nutrient deprivation conditions. The extent to which these findings generalize across diverse cancer types, particularly those with differing p53 or c-MYC status, remains to be determined. Additionally, while pharmacological ATM inhibitors were used, off-target effects or compensatory pathways in vivo could influence the observed outcomes. Transferability to clinical settings will require careful evaluation, including assessment of toxicity and the feasibility of targeting macropinocytosis in patients.

Protocol Parameters

• ATM kinase inhibition: Apply a selective ATM kinase inhibitor at concentrations validated by cell viability and macropinocytosis assays (dose ranges in the reference paper were optimized for each cell type).
• Macropinocytosis assay: Use fluorescent dextran uptake (e.g., 70 kDa FITC-dextran) and quantify by flow cytometry or fluorescence microscopy after defined incubation periods (commonly 30–60 minutes).
• Nutrient deprivation: Culture cells in amino acid-restricted or serum-free media to induce metabolic stress and assess adaptive responses.
• BCAA supplementation: Add defined concentrations of branched-chain amino acids (e.g., 2 mM leucine, 2 mM isoleucine) to abrogate macropinocytosis induction, as demonstrated in the study.
• In vivo workflow: For xenograft models, administer ATM kinase inhibitor orally at doses consistent with preclinical pharmacokinetics, and combine with macropinocytosis inhibitors as appropriate for mechanistic studies.

Research Support Resources

For researchers aiming to replicate or expand upon these findings, selective ATM kinase inhibitors remain critical tools. AZD0156 (SKU B7822) from APExBIO is an orally bioavailable, potent, and highly selective ATM kinase inhibitor, suitable for both in vitro and in vivo studies. Its well-characterized selectivity profile and compatibility with DNA damage response and metabolic adaptation assays make it a practical choice for dissecting the interplay between DNA double-strand break repair, checkpoint control, and nutrient scavenging pathways.